/ATTBF

ATTBF Stock - Abattis Bioceuticals Corp.

Q: What is the analyst price target for ATTBF?

Analyst price target information is not currently available for ATTBF.

Q: What is ATTBF's market cap?

Market capitalization information is not currently available for ATTBF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ATTBF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2015

FY2016

FY2017

FY2018

FY2019

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-46.51

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2019	FY2018	FY2017	FY2016	FY2015
Revenue	$356,876	$8,371	N/A	N/A	$91,940
Gross Profit	$241,336	$6,477	N/A	N/A	$62,621
Gross Margin	67.6%	77.4%	N/A	N/A	68.1%
Operating Income	$-3,956,802	$-17,373,360	$-6,361,499	$-2,305,054	$-3,077,757
Net Income	$-3,042,005	$-78,012,707	$-7,634,062	$-2,339,416	$-4,472,547
Net Margin	-852.4%	-931940.1%	N/A	N/A	-4864.6%
EPS	$-0.01	$-0.24	$-0.05	$-0.02	$-0.07

Company Overview

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Visit Website

Frequently Asked Questions about ATTBF

What is ATTBF's current stock price?

Abattis Bioceuticals Corp. (ATTBF) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for ATTBF?

No analyst price targets are currently available for this stock.

What sector is Abattis Bioceuticals Corp. in?

Abattis Bioceuticals Corp. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is ATTBF's market cap?

Abattis Bioceuticals Corp. has a market capitalization of $0.00 billion, making it a small-cap company.

Does ATTBF pay dividends?

No, Abattis Bioceuticals Corp. does not currently pay a dividend to shareholders.